Chris Reynolds

Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide + Rituximab (R2) Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin

Introduction:Patients with relapsed indolent NHL (iNHL) have limited standard treatment options. Lenalidomide combined with rituximab (R ) has shown complimentary clinical activity and is...

Jung R. Ahn ;

Ju Li ;

Mathias D. Rummel ;

Jeff P. Sharman ;

Frederick Lansigan ;

David J. Andorsky ;

Morton Coleman ;

Yacoub Abdulraheem ;

Jason M. Melear ;

Suzanne R. Fanning ;

Kathryn S. Kolibaba ;

Chris Reynolds ;

Grzegorz S. Nowakowski ;

Mecide Gharibo ;

11/04/2022

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Chris Reynolds

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products